ID   DM331
AC   CVCL_6626
SY   Duke Melanoma 331
DR   cancercelllines; CVCL_6626
DR   GEO; GSM1671956
DR   GEO; GSM1671958
DR   GEO; GSM1671963
DR   GEO; GSM1671971
DR   GEO; GSM1671973
DR   GEO; GSM1671979
DR   GEO; GSM1671992
DR   GEO; GSM1671994
DR   GEO; GSM1671999
DR   GEO; GSM1672010
DR   GEO; GSM1672028
DR   GEO; GSM1672031
DR   GEO; GSM1672033
DR   GEO; GSM1672034
DR   GEO; GSM1672037
DR   GEO; GSM1672052
DR   GEO; GSM1672057
DR   GEO; GSM1672058
DR   Wikidata; Q54831215
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   From: Duke University Medical Center; Durham; USA.
CC   HLA typing: A*01,02; B*15,62 (PubMed=10752474).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Right axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=10752474; DOI=10.1007/s002620050015;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. III,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. III, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//